New scientific works about Phage Therapy

PDF

PDF

From IDSA

2012:Exploiting bacteriophages for bioscience, biotechnology and medicine.

Web site

I have selected this:

 

http://www.ampliphibio.com

Mycobacterium phages for Mycobacterium ulcerans

Mycobacterium phage TM4, complete genome

Genome Info:	Features:	BLAST homologs:	Links:	Review Info:
Refseq: NC_003387	Genes: 89	COG	Genome Project	Publications: [1]
GenBank: AF068845	Protein coding: 89	TaxMap	Refseq FTP	Refseq Status: Validated
Length: 52,797 nt	Structural RNAs: None	TaxPlot	GenBank FTP	Seq.Status: Completed
GC Content: 68%	Pseudo genes: None	GenePlot	BLAST	Sequencing center: University of Pittsburgh, Biological Sciences, USA, Pittsburgh
% Coding: 91%	Others: None	gMap	TraceAssembly	Completed: 1999/03/04
Topology: linear	Contigs: None		CDD	Organism Group
Molecule: dsDNA			Other genomes for species:

Mycobacterium phage L5, complete genome

Genome Info:	Features:	BLAST homologs:	Links:	Review Info:
Refseq: NC_001335	Genes: 88	COG	Genome Project	Publications: [2]
GenBank: Z18946	Protein coding: 85	TaxMap	Refseq FTP	Refseq Status: Validated
Length: 52,297 nt	Structural RNAs: 3	TaxPlot	GenBank FTP	Seq.Status: Completed
GC Content: 62%	Pseudo genes: None	GenePlot	BLAST	Sequencing center: Graham F Hatfull Dr, Biological Sciences, University of, Pittsburgh, Department of Biological Sciences, University of, Pittsburgh, Pittsburgh, PA, 15260, USA
% Coding: 87%	Others: 3	gMap	TraceAssembly	Completed: 1993/02/23
Topology: linear	Contigs: None		CDD	Organism Group
Molecule: dsDNA			Other genomes for species:

Mycobacterium phage D29, complete genome

Genome Info:	Features:	BLAST homologs:	Links:	Review Info:
Refseq: NC_001900	Genes: 84	COG	Genome Project	Publications: [1]
GenBank: AF022214	Protein coding: 79	TaxMap	Refseq FTP	Refseq Status: Reviewed
Length: 49,136 nt	Structural RNAs: 5	TaxPlot	GenBank FTP	Seq.Status: Completed
GC Content: 63%	Pseudo genes: None	GenePlot	BLAST	Sequencing center: University of Pittsburgh, Biological Sciences, USA, Pittsburgh
% Coding: 90%	Others: 3	gMap	TraceAssembly	Completed: 1998/06/02
Topology: linear	Contigs: None		CDD	Organism Group
Molecule: dsDNA			Other genomes for species:

Link 1

Link2
Link3
Link4
Link5 
Link6 
Link7
Link8
Link9

Mycobacterium ulcerans Agy99, complete genome

Mycobacterium ulcerans Agy99, complete genome

Chromosomes: genome
Plasmids: pMUM001

Genome Info:	Features:	BLAST homologs:	Links:	Review Info:
Refseq: NC_008611	Genes: 4981	COG	Genome Project	Publications: [1]
GenBank: CP000325	Protein coding: 4160	TaxMap	Refseq FTP	Refseq Status: PROVISIONAL
Length: 5,631,606 nt	Structural RNAs: 50	TaxPlot	GenBank FTP	Seq.Status: Completed
GC Content: 65%	Pseudo genes: 771	GenePlot	BLAST	Sequencing center: Institut Pasteur
% Coding:   72%	Others: 452	gMap	TraceAssembly	Completed: 2006/12/04
Topology: circular	Contigs: None		CDD	Organism Group
Molecule: DNA			Other genomes for species:

Gene Classification based on COG functional categories

Link1 Link2 Link3 Link4 Link5

Antimicrobial Research ( SAR-2011)

Web site

Phage therapy conditions

Phage therapy must be used in those conditions  where the therapeutic success is elevated a priori.

Why?

a-Because Phage Therapy must maintain its best advantage :   the RAPIDITY "GO, KILL and  DISAPPEAR".

b- Because Phages must be Lytic and not modified by genetic engineering.

c-Because when we use the natural lytic phages in this SHORT TIME  IS IMPOSSIBLE to have:
 - a bacterial resistance that stops a phage attack ( 12 generations are necessary after a mutation of phage receptor in one bacterium for one phage and for this raison we use a minimum  of two phages in the cocktail).
- an active  immunological reaction ( two weeks are necessary).

d-Because it  is hard now to select phages and to prepare a phage cocktail by natural phages we can imagine how this  will be  with  transformed phages.


 e-Because with recombinant phages it is impossible to predict what will happen regarding the therapy and also  the phage preparation  is complicated and  the use of these phages do not avoid  the appearance of Phage Resistance.

 f-For impeding the effect of the Endotoxin it is possible to use the Polimixina B.

If the abovementioned points are not adequately covered  we must not use Phage Therapy .

Clinical Trials for phage therapy

Clinical Trials for phage therapy

Sampling techniques for laboratory diagnosis of Buruli ulcer

From:




Presentation
PDF document


Buruli and the best stage for the therapy

Salmonella: The New Superbug

From Medscape

Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy